Bittium Corporation
Inside Information
Inside Information: Bittium Corporation's Subsidiary Bittium Biosignals Ltd. and
Boston Scientific Have Signed an Agreement for the Supply of Electrocardiogram
Monitoring Devices
Bittium Corporation, Stock Exchange Release, 4 June 2025, at 5.30 pm (CEST+1)
Bittium Biosignals Ltd, a subsidiary of Bittium Corporation, and Boston
Scientific Cardiac Diagnostics, Inc., a fully owned subsidiary of Boston
Scientific Corporation, have today signed a new agreement by which Bittium will
supply electrocardiogram (ECG) measuring devices for monitoring cardiac
arrhythmias. The companies will also continue to collaborate on the development
of tailored ECG technologies.
The total value of the new agreement will be approximately USD 30-45 million
(approximately EUR 26-41 million based on an exchange rate of 3 June 2025), with
revenues accruing during 2025-2028. The final value of the agreement is
depending on the scope and execution of the agreement over its term. The
agreement is effective as of today, 4 June 2025, and replaces the existing
agreement, signed on 2 February 2022.
The cooperation between Bittium and Boston Scientific regarding the development
and delivery of wireless ECG measurement devices began in 2018. Bittium offers
state-of-the-art ECG technology, which, together with Boston Scientific has been
customized and further developed to improve the physician and patient experience
in remote cardiac monitoring.
Boston Scientific has the exclusive right to use, resell and market customized
ECG devices as part of its remote diagnostic services offering in the United
States. The product family of ECG sensors continuously records
electrocardiographic waveforms and provides multiple uses across Bittium
devices, including short- and long-term Holter measurements, Cardiac Event
Monitoring (CEM) and Mobile Cardiac Telemetry (MCT).
“We are happy to continue the strategic partnership with Boston Scientific as
our collaborative relationship has helped develop modern tools for healthcare
professionals in diagnosing patients with suspected arrhythmias,” says Niina
Huikuri, Senior Vice President, Medical Business Segment of Bittium.
In Oulu, Finland, on 4 June 2025,
Petri Toljamo
CEO
Bittium Corporation
Further information:
Karoliina Malmi
Vice President, Communications & Sustainability
Tel. +358 40 344 2789
Distribution
Nasdaq Helsinki Oy
Main media
Bittium
Bittium specializes in the development of reliable, secure communications and
connectivity solutions leveraging its 40-year legacy of expertise in advanced
radio communication technologies. Bittium provides innovative products and
services, customized solutions based on its product platforms and R&D services.
Complementing its communications and connectivity solutions, Bittium offers
proven information security solutions for mobile devices and portable computers.
Bittium also provides healthcare technology products and services for biosignal
measuring in the areas of cardiology and neurophysiology. Net sales in 2024 were
EUR 85.2 million and operating profit was EUR 8.6 million. Bittium is listed on
Nasdaq Helsinki. www.bittium.com
Boston Scientific
Boston Scientific Cardiac Diagnostics, Inc. is a wholly owned subsidiary of
Boston Scientific Corporation. Boston Scientific transforms lives through
innovative medical technologies that improve the health of patients around the
world. As a global medical technology leader for more than 45 years, we advance
science for life by providing a broad range of high-performance solutions that
address unmet patient needs and reduce the cost of healthcare. Learn more at
www.bostonscientific.com and connect
on LinkedIn (https://c212.net/c/link/?t=0&l=en&o=4416063
-1&h=3538564391&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fboston
-scientific%2F&a=LinkedIn+)and X (https://c212.net/c/link/?t=0&l=en&o=4416063
-1&h=99427925&u=https%3A%2F%2Ftwitter.com%2Fbostonsci&a=X).